{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T22:06:04Z","timestamp":1794002764939,"version":"4.8.0"},"reference-count":40,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic cell transplantation (alloHCT) often represents the only curative treatment for various malignant and nonmalignant disorders. Initially, the only suitable donors were considered human leukocyte antigen (HLA)\u2013matched or partially matched relatives. The founding of international unrelated donor and umbilical cord blood registries expanded unrelated donor options and access for patients. In the absence of a matched sibling donor (MSD) with 13% to 51% availability, the current consensus recommends use of a matched unrelated donor (MUD) at HLA-A, B, C, and DRB1 with consideration of matching at HLA-DPB1 and -DQB1. MUD donor availability (donor willing and available to donate) ranges from 29% to 78% with African American patients on the lower end and white non-Hispanic patients with the highest likelihood of a match. Recent studies comparing donor to no-donor treatment options in malignant disease consistently point to substantially better outcomes following alloHCT. In the absence of an MSD or MUD, alternative donor choices turn to haploidentical related (Haplo), mismatched unrelated donor (MMUD), and umbilical cord blood (UCB). Novel strategies for alloHCT, including the use of posttransplant cyclophosphamide-based graft vs host disease prophylaxis, have expanded the safety and effectiveness of transplant procedures across HLA barriers using Haplo and MMUD. The less restrictive matching requirements for UCB transplant are well documented and allow for transplant across multiply mismatched HLA alleles. When all donor options are considered, nearly all patients have an available donor. Here we discuss the likelihood of donor availability, complete HLA match by available donor type, and current controversies warranting future research.<\/jats:p>","DOI":"10.1182\/hematology.2022000326","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T11:16:10Z","timestamp":1670584570000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Hematology 2022\u2014what is complete HLA match in 2022?"],"prefix":"10.1182","volume":"2022","author":[{"given":"Stephen R.","family":"Spellman","sequence":"first","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, National Marrow Donor Program\/Be The Match, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"9 suppl","key":"2022121313285177000_hem2022000326C1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.bbmt.2008.05.001","article-title":"Advances in the selection of HLA-compatible donors: refinements in HLA typing and matching over the first 20 years of the National Marrow Donor Program Registry","volume":"14","author":"Spellman","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2022121313285177000_hem2022000326C2","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1182\/blood-2011-05-353490","article-title":"Definitions of histocompatibility typing terms","volume":"118","author":"Nunes","year":"2011","journal-title":"Blood"},{"issue":"5","key":"2022121313285177000_hem2022000326C3","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"21","key":"2022121313285177000_hem2022000326C4","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1200\/JCO.20.03643","article-title":"Impact of previously unrecognized HLA mismatches using ultrahigh resolution typing in unrelated donor hematopoietic cell transplantation","volume":"39","author":"Mayor","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2022121313285177000_hem2022000326C5","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2015.09.012","article-title":"On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source","volume":"22","author":"Besse","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2022121313285177000_hem2022000326C6","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"2022121313285177000_hem2022000326C7","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1200\/JCO.20.03502","article-title":"National Marrow Donor Program-sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant cyclophosphamide","volume":"39","author":"Shaw","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"2022121313285177000_hem2022000326C8","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1182\/bloodadvances.2021004192","article-title":"Posttransplant cyclophosphamide as GVHD prophylaxis for peripheral blood stem cell HLA-mismatched unrelated donor transplant","volume":"5","author":"Al Malki","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2022121313285177000_hem2022000326C9","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.bbmt.2020.07.030","article-title":"Guidelines for cord blood unit selection","volume":"26","author":"Politikos","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2022121313285177000_hem2022000326C10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2022121313285177000_hem2022000326C11","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.2020007535","article-title":"Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial","volume":"137","author":"Fuchs","year":"2021","journal-title":"Blood"},{"issue":"2","key":"2022121313285177000_hem2022000326C12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood-2015-08-663823","article-title":"The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy","volume":"127","author":"Kollman","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2022121313285177000_hem2022000326C13","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.bbmt.2018.02.006","article-title":"Development of an unrelated donor selection score predictive of survival after HCT: donor age matters most","volume":"24","author":"Shaw","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2022121313285177000_hem2022000326C14","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Adv"},{"issue":"13","key":"2022121313285177000_hem2022000326C15","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1182\/blood-2012-08-453860","article-title":"Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?","volume":"121","author":"Alousi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2022121313285177000_hem2022000326C16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamaoncol.2021.6846","article-title":"Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors","volume":"8","author":"Guru Murthy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"2","key":"2022121313285177000_hem2022000326C17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2022121313285177000_hem2022000326C18","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1200\/JCO.2018.79.2184","article-title":"Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation","volume":"37","author":"Frick","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"2022121313285177000_hem2022000326C19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.21.02286","article-title":"Donor clonal hematopoiesis and recipient outcomes after transplantation","volume":"40","author":"Gibson","year":"2022","journal-title":"J Clin Oncol"},{"issue":"12","key":"2022121313285177000_hem2022000326C20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood.2019001212","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR","volume":"134","author":"Dehn","year":"2019","journal-title":"Blood"},{"issue":"13","key":"2022121313285177000_hem2022000326C21","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1182\/blood-2007-06-097386","article-title":"High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation","volume":"110","author":"Lee","year":"2007","journal-title":"Blood"},{"issue":"16","key":"2022121313285177000_hem2022000326C22","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2014-05-576041","article-title":"Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation","volume":"124","author":"Pidala","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2022121313285177000_hem2022000326C23","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.bbmt.2010.09.012","article-title":"HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation","volume":"17","author":"Woolfrey","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2022121313285177000_hem2022000326C24","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood-2012-03-417758","article-title":"Evaluation of HLA matching in unrelated hematopoietic stem cell transplantation for nonmalignant disorders","volume":"120","author":"Horan","year":"2012","journal-title":"Blood"},{"issue":"18","key":"2022121313285177000_hem2022000326C25","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2013-02-482547","article-title":"High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis","volume":"122","author":"F\u00fcrst","year":"2013","journal-title":"Blood"},{"issue":"4","key":"2022121313285177000_hem2022000326C26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(12)70004-9","article-title":"Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study","volume":"13","author":"Fleischhauer","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"2022121313285177000_hem2022000326C27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41409-019-0694-y","article-title":"Protective effect of HLA-DPB1 mismatch remains valid in reduced-intensity conditioning unrelated donor hematopoietic cell transplantation","volume":"55","author":"Malki","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"2022121313285177000_hem2022000326C28","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood.2022015708","article-title":"A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell transplantation","volume":"140","author":"Arrieta-Bola\u00f1os","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2022121313285177000_hem2022000326C29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bbmt.2016.10.021","article-title":"Identification of DPB1 permissive unrelated donors is highly likely","volume":"23","author":"Tram","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2022121313285177000_hem2022000326C30","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.humimm.2021.06.010","article-title":"Predicting HLA-DPB1 permissive probabilities through a DPB1 prediction service towards the optimization of HCT donor selection","volume":"82","author":"Sajulga","year":"2021","journal-title":"Hum Immunol"},{"issue":"1","key":"2022121313285177000_hem2022000326C31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation","volume":"55","author":"Ciurea","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"2022121313285177000_hem2022000326C32","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1182\/bloodadvances.2020003110","article-title":"Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide","volume":"4","author":"Solomon","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2022121313285177000_hem2022000326C33","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S2352-3026(19)30208-X","article-title":"Role of HLA-B exon 1 in graft-versus-host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study","volume":"7","author":"Petersdorf","year":"2020","journal-title":"Lancet Haematol"},{"issue":"10","key":"2022121313285177000_hem2022000326C34","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood.2021013443","article-title":"HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide","volume":"139","author":"Fuchs","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2022121313285177000_hem2022000326C35","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bbmt.2011.09.008","article-title":"Scoring HLA class I mismatches by HistoCheck does not predict clinical outcome in unrelated hematopoietic stem cell transplantation","volume":"18","author":"Spellman","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2022121313285177000_hem2022000326C36","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood-2013-10-532671","article-title":"Identification of a permissible HLA mismatch in hematopoietic stem cell transplantation","volume":"123","author":"Fernandez-Vi\u00f1a","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2022121313285177000_hem2022000326C37","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1182\/blood-2013-01-480343","article-title":"The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem cell transplantation with unrelated donors","volume":"121","author":"Hurley","year":"2013","journal-title":"Blood"},{"issue":"22","key":"2022121313285177000_hem2022000326C38","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.1182\/blood-2013-02-481945","article-title":"Multiple mismatches at the low expression HLA loci DP, DQ, and DRB3\/4\/5 associate with adverse outcomes in hematopoietic stem cell transplantation","volume":"121","author":"Fern\u00e1ndez-Vi\u00f1a","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2022121313285177000_hem2022000326C39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1182\/blood-2013-05-506253","article-title":"Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy","volume":"123","author":"Eapen","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2022121313285177000_hem2022000326C40","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/bmt.2016.162","article-title":"Unrelated donor search prognostic score to support early HLA consultation and clinical decisions","volume":"51","author":"Wadsworth","year":"2016","journal-title":"Bone Marrow Transplant"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/83\/2023039\/83spellman.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/83\/2023039\/83spellman.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T08:31:52Z","timestamp":1670920312000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/83\/493558\/Hematology-2022-what-is-complete-HLA-match-in-2022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000326","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}